Zobrazeno 1 - 10
of 194
pro vyhledávání: '"Mitchell S. Steiner"'
Autor:
Ramesh Narayanan, James T. Dalton, Duane D. Miller, Mitchell S. Steiner, Juhyun Kim, Christina M. Barrett, Feng Yin, Anand Kulkarni, Zhongzhi Wu, Muralimohan Yepuru
Supplementary Methods - PDF file 62K, Additional methods to support the manuscript 1. Cloning and protein purification 2. AKR1C3 enzyme activity and thin layer chromatography (TLC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b61fd5c570260e577b177036fb6ded0
https://doi.org/10.1158/1078-0432.22448303
https://doi.org/10.1158/1078-0432.22448303
Autor:
Emmanuel S. Antonarakis, Mario A. Eisenberger, Daniel R. Saltzstein, Mitchell S. Steiner, Domingo Rodriguez, Robert H. Getzenberg, K. Gary Barnette, Christopher Pieczonka, Ronald Tutrone, Mark C. Markowski
Supplementary Table from A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2456e88fae6612bcc1aa1dc04ef0392d
https://doi.org/10.1158/1078-0432.22487445
https://doi.org/10.1158/1078-0432.22487445
Autor:
Emmanuel S. Antonarakis, Mario A. Eisenberger, Daniel R. Saltzstein, Mitchell S. Steiner, Domingo Rodriguez, Robert H. Getzenberg, K. Gary Barnette, Christopher Pieczonka, Ronald Tutrone, Mark C. Markowski
Purpose:Sabizabulin, an oral cytoskeleton disruptor, was tested in a phase Ib/II clinical study in men with metastatic castration-resistant prostate cancer (mCRPC).Patients and Methods:The phase Ib portion utilized a 3+3 design with escalating daily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50421e19a001661970dc656f5da91e86
https://doi.org/10.1158/1078-0432.c.6532521.v1
https://doi.org/10.1158/1078-0432.c.6532521.v1
Autor:
Emmanuel S. Antonarakis, Mario A. Eisenberger, Daniel R. Saltzstein, Mitchell S. Steiner, Domingo Rodriguez, Robert H. Getzenberg, K. Gary Barnette, Christopher Pieczonka, Ronald Tutrone, Mark C. Markowski
Supplementary Data from A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2690f8bd90f324f5452f619598ac5277
https://doi.org/10.1158/1078-0432.22487460.v1
https://doi.org/10.1158/1078-0432.22487460.v1
Autor:
Ramesh Narayanan, James T. Dalton, Duane D. Miller, Mitchell S. Steiner, Juhyun Kim, Christina M. Barrett, Feng Yin, Anand Kulkarni, Zhongzhi Wu, Muralimohan Yepuru
Purpose: Castration-resistant prostate cancer (CRPC) may occur by several mechanisms including the upregulation of androgen receptor (AR), coactivators, and steroidogenic enzymes, including aldo keto reductase 1C3 (AKR1C3). AKR1C3 converts weaker 17-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a57a15623b8fedd853cd24db1376c413
https://doi.org/10.1158/1078-0432.c.6521366.v1
https://doi.org/10.1158/1078-0432.c.6521366.v1
Autor:
Emmanuel S. Antonarakis, Mario A. Eisenberger, Daniel R. Saltzstein, Mitchell S. Steiner, Domingo Rodriguez, Robert H. Getzenberg, K. Gary Barnette, Christopher Pieczonka, Ronald Tutrone, Mark C. Markowski
Supplementary Figure from A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63891b5c4b7c0b8c1a20f44ba0ce493b
https://doi.org/10.1158/1078-0432.22487457
https://doi.org/10.1158/1078-0432.22487457
Autor:
Ramesh Narayanan, James T. Dalton, Duane D. Miller, Mitchell S. Steiner, Juhyun Kim, Christina M. Barrett, Feng Yin, Anand Kulkarni, Zhongzhi Wu, Muralimohan Yepuru
Supplementary Figures and Tables - PDF file 898K, Supplementary Table ST1: AKR1C3 over-expression in HEK-293 cells reduces IC50 of androgens. Supplementary Table ST2: Finasteride increases the testosterone formation. Supplementary Figure S1: Over-exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2313844cbd6f85fde36c7fde87d3e444
https://doi.org/10.1158/1078-0432.22448306
https://doi.org/10.1158/1078-0432.22448306
Autor:
Mark C. Markowski, Ronald Tutrone, Christopher Pieczonka, K. Gary Barnette, Robert H. Getzenberg, Domingo Rodriguez, Mitchell S. Steiner, Daniel R. Saltzstein, Mario A. Eisenberger, Emmanuel S. Antonarakis
Publikováno v:
Clin Cancer Res
Purpose: Sabizabulin, an oral cytoskeleton disruptor, was tested in a phase Ib/II clinical study in men with metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods: The phase Ib portion utilized a 3+3 design with escalating dai
Autor:
Adam Brufsky, Hannah Linden, Hope Rugo, Charles Vogel, Joyce A O'Shaughnessy, Robert H Getzenberg, K. Gary Barnette, Domingo Rodriguez, Mitchell S Steiner, Erica Mayer
Publikováno v:
Cancer Research. 82:OT2-17
Targeting the androgen receptor (AR) may be the next important endocrine therapy for women with advanced breast cancer. AR is the most abundantly expressed steroid receptor in breast cancer and has been demonstrated to be a tumor suppressor when acti
Publikováno v:
Asian Journal of Andrology, Vol 16, Iss 2, Pp 256-261 (2014)
Several testosterone preparations are used in the treatment of hypogonadism in the ageing male. These therapies differ in their convenience, flexibility, regional availability and expense but share their pharmacokinetic basis of approval and dearth o
Externí odkaz:
https://doaj.org/article/cb7a209083cf49388d5dbc9bca43efe1